Home Cart Sign in  
Chemical Structure| 331001-62-8 Chemical Structure| 331001-62-8

Structure of IQ 1
CAS No.: 331001-62-8

Chemical Structure| 331001-62-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

IQ-1 enables Wnt/β-catenin-driven expansion of mouse ESCs and prevents spontaneous differentiation, Maintains embryonic stem cell (ESC) pluripotency in Wnt3a-treated cells and prevents PP2A/Nkd interaction.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of IQ 1

CAS No. :331001-62-8
Formula : C21H22N4O2
M.W : 362.43
SMILES Code : O=C(N)C(/N=N/C1=CC=C(C(C)=O)C=C1)=C2NC(C)(C)CC3=C\2C=CC=C3
MDL No. :MFCD00354369

Safety of IQ 1

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nude mice HER2-positive gastric cancer xenograft model Intraperitoneal injection 20 mg/kg Twice a week for 4 weeks To evaluate the effect of trastuzumab and BPTES on the HER2-positive gastric cancer xenograft model. The results showed that trastuzumab-sensitive tumors were significantly suppressed after trastuzumab treatment, while the tumor volume of the trastuzumab-resistant group treated with trastuzumab or BPTES alone did not significantly change compared with the trastuzumab-sensitive group. Interestingly, BPTES combined with trastuzumab reduced the tumor size compared to the trastuzumab-resistant group treated with trastuzumab alone, similar to the trastuzumab-sensitive group treated with trastuzumab. PMC10397568

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.76mL

0.55mL

0.28mL

13.80mL

2.76mL

1.38mL

27.59mL

5.52mL

2.76mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories